On November 17, 2021, Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in financing. Atlas Venture and Newpath Partners seeded the company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T. Rowe Price Associates, Inc., and Wellington Management, in addition to all seed investors. The financing will support continued development of the company's epigenetic editing platform and advancement of its pipeline of targeted therapeutics. Wilson Sonsini Goodrich & Rosati advised Chroma on patent and technology transactions matters related to the financing and launch.

Chroma's modular epigenetic editors can be precisely programmed to durably turn genes on or off or alter the expression of several genes at once. This approach represents a step change advance in gene editing, enabling the company to seamlessly silence, activate, and multiplex genes in a single platform. Chroma's epigenetic editors have the potential to address a wide range of diseases and to become the technology of choice for gene regulation.

Chroma launches with partnerships with world-renowned academic institutions. Its recent acquisition of Milan, Italy-based Epsilen Bio seeded by Sofinnova Partners and founded by Angelo Lombardo, Ph.D. and Luigi Naldini, M.D., Ph.D., adds complementary capabilities through a partnership with the San Raffaele Telethon Institute for Gene Therapy, a joint institute between Ospedale San Raffaele and Fondazione Telethon, a pioneer in cell and gene therapy. The company also launches with collaborations with Massachusetts General Hospital and the University of California, San Francisco, global leaders in scientific innovation and genetic disease research.

The Wilson Sonsini team that represented Chroma in the transaction includes patent attorneys Lou Lieto and Angel Wang, patent agent Sarah Cohen, and technology transactions attorneys Farah Gerdes and Miruna Predescu.

For more information, please see Chroma's press release.